한국보건의료기술평가학회
 
 
 

 Original Article


다운로드 #1 : 0602014010_강혜영.pdf (1 MB)


Decision Making Based on Incremental Cost-Effectiveness Ratio for Anticancer Drugs
항암제 경제성평가에서 점증적 비용-효과비와 의사결정

Hoe Sang Kim, MS1, Young-Ju Kang, MS2, Su-Kyung Ko, PhD3, and Hye-Young Kang, PhD4
김회상1·강영주2·고수경3·강혜영4
1Jongno-gu Public Health Center, Seoul, Korea 2The Korean Research-Based Pharmaceutical Industry Association, Seoul, Korea 3Pfizer Korea, Seoul, Korea 4College of Pharmacy, Yonsei Research Institute of Pharmaceu
종로구 보건소1, 한국다국적의약산업협회2, 한국화이자3, 연세대학교 약학대학, 연세대학교 종합약학연구소4


Corresponding Author: Hye-Young Kang, PhD ,Tel: +82-32-749-4512, Fax: +82-32-749-4105, Email: hykang2@yonsei.ac.kr
 
 Abstract

Objectives: To discuss potential problems of reimbursement decision making for anti-cancer drugs based on incremental cost-effectiveness ratio (ICER), and to examine alternative approaches that can replace ICER. Methods: Literature review was conducted for peer-review journals published from 2006 and 2010 using a structured search strategy. Web-site search was carried out for documentation provided by health technology assessment institutes for selected countries including England, Canada, and Australia. Results: To improve access to anti-cancer drugs, two alternative approaches for ICER criteria were discussed: variable ICER threshold and multi-criteria decision analysis (MCDA). Variable ICER threshold indicates to use different ICER threshold for different types of disease or population to reflect distinct characteristics, expectation, and value associated with specific disease or population. MCDA suggests to use multiple criteria such as rare condition, equity, equality, needs, as well as efficiency, in order to fully reflect social value of medicine. Pros and cons of these alternative approaches were discussed. Conclusion: To employ these alternative approaches in reimbursement and/or pricing decision making for anti-cancer drugs, specific methods to operationalize and measure each criterion of MCDA and disease-specific ICER value should be developed. Further, the developed methods requires consensus by members of society.

Key Words Cancer · Incremental cost-effectiveness ratio · Social value · Threshold.
 
 


 
개인정보취급방침 (06974) 서울 동작구 흑석로 84 중앙대학교 약학대학 102관 611호 kahta@hanmail.net
Copyright 2015 KAHTA All Rights Reserved.